IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Immix Biopharma 12 Month Review Progress Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial.
The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.
/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.